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Background: Although capecitabine has theoretical advantages in the pharmacokinetics, such as higher
intratumoral and lower systemic concentration, relative to bolus 5-fluorouracil (5-FU), outcomes of
chemoradiotherapy (CRT) with capecitabine or bolus 5-FU have not been directly compared in patients with locally
advanced pancreatic cancer. Therefore, we retrospectively compared the outcomes, including toxicity, tumor
response, and overall survival, of oral capecitabine plus radiotherapy (RT) with bolus 5-FU plus RT, in patients with
locally advanced pancreatic cancer.
Methods: Between August 2006 and January 2012, 98 patients with locally advanced pancreatic cancer received
CRT, with 52 receiving concurrent oral capecitabine and 46 receiving bolus injection of 5-FU. Primary tumor and
overall response after CRT were evaluated radiologically, and toxicity, tumor response, and overall survival (OS) were
compared in the two groups.
Results: Baseline clinical parameters of the two groups were similar. The rates of ≥ Grade 3 hematologic (0% vs.
8.7%, p = 0.045) and non-hematologic (0% vs. 8.7%, p = 0.045) toxicities were significantly lower in the capecitabine
group than in the 5-FU group. Primary tumor (30.7% vs. 28.2%, p = 0.658) and overall (13.7% vs. 15.2%, p = 0.273)
response rates and median OS time (12.5 months vs. 11.6 months, p = 0.655) were similar in the two groups.
Conclusions: Capecitabine plus RT may be a safe and feasible regimen for patients with locally advanced
pancreatic cancer, with similar efficacy and low rates of toxicities compared with bolus 5-FU plus RT.
Keywords: Pancreatic cancer, Chemoradiotherapy, 5-Fluorouracil, CapecitabineIntroduction
Surgical resection is the only curative treatment for pancre-
atic cancer, but only 10–15% of patients have localized and
resectable disease at diagnosis. Approximately 50% of pan-
creatic cancer patients present with distant metastatic dis-
ease and 30% present with localized and unresectable
disease. The Gastrointestinal Tumor Study Group (GITSG)
trials [1-3] showed that chemoradiotherapy (CRT) with
bolus injection of 5-fluorouracil (5-FU) yielded a modest
survival benefit when compared with radiotherapy (RT) or
chemotherapy alone. Since then, CRT plus bolus 5-FU has* Correspondence: k2onco@naver.com
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reproduction in any medium, provided the orbeen regarded as a standard therapy for patients with locally
advanced pancreatic cancer. Despite recent advances in
diagnostics and therapeutics, the prognosis of patients with
locally advanced pancreatic cancer has remained poor, due
to high rates of local progression and distant metastasis.
Thus, various chemotherapeutic regimens, with various dos-
ages and schedules and with or without RT, have been tested
to improve survival [4-8].
Capecitabine, an oral prodrug of 5-FU, is absorbed by
the gastrointestinal tract and metabolized to 5-FU by a
cascade of three enzymes. Capecitabine is converted by
carboxylesterase in the liver to 5′-deoxy-5-fluorocytidine
(5′-DFCR), by cytidine deaminase in the liver and tumor
tissue to 5′-deoxy-5-fluorouridine (5′-DFUR), and by
thymidine phosphorylase (TP) to 5-FU in tumor tissue.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tissue, and is upregulated by radiation in tumor tissue
but not in normal tissue. Thus, oral capecitabine can re-
sult in a higher intratumoral and lower systemic 5-FU
concentration than bolus 5-FU [9,10]. This improved
therapeutic index, along with more favorable pharmaco-
kinetics (similar to those of protracted infusion of 5-FU),
and convenient oral administration without the need for
central venous access and an ambulatory infusion pump,
make capecitabine particularly appealing to use in con-
junction with RT. To our knowledge, however, outcomes
of CRT with capecitabine or bolus 5-FU have not been
directly compared in patients with locally advanced pan-
creatic cancer. We therefore retrospectively compared
the outcomes, including toxicity, tumor response, and
overall survival, of oral capecitabine plus RT with bolus




Between August 2006 and January 2012, 52 patients with
primary locally advanced pancreatic cancer underwent
CRT with capecitabine under a phase II protocol. Eligi-
bility criteria included: (1) pathologically confirmed pan-
creatic carcinoma; (2) unresectable disease (stage cT4)
on computed tomography (CT)/positron-emission tom-
ography (PET); (3) radiographically assessable disease;
(4) age ≥ 18 years; (5) performance status of 0 to 1 on
the Eastern Cooperative Oncology Group (ECOG) score;
(6) adequate bone marrow (white blood cell count ≥
2,000/mm3, hemoglobin ≥ 7.5 g/dL, platelet count ≥
100,000/mm3), liver (total bilirubin ≤ 3.0 mg/dL), and
renal (serum creatinine ≤ 1.5 mg/dL) function; and (7)
oral intake (including J-tube feeding) of ≥ 1,500 calories/
day. Patients with elevated bilirubin due to obstruction
were stented and their bilirubin decreased to ≤ 3.0 mg/
dL, and patients with biliary or gastroduodenal obstruc-
tion underwent drainage prior to study entry. Exclusion
criteria included: (1) radiographic evidence of metastasis
in the major viscera or peritoneal seeding on CT and/or
PET; (2) previous history of RT adjacent to the planned
field; (3) pregnancy or breast feeding; and (4) previous
history of uncontrolled other malignancies within 2 years.
All patients provided written informed consent before
study enrollment and this trial was registered at
clinicaltrials.gov (NCT00658840).
During the same study period, 46 patients who refused
to participate in this protocol received CRT plus 5-FU,
the routine clinical practice regimen in our institution
for patients with locally advanced pancreatic cancer.
This study was conducted in accordance with the guide-
lines of the institutional review boards of the National
Cancer Center.Before CRT, patients were given physical examinations
and underwent blood tests, including complete blood
count, liver function tests, and serum CA 19–9 concen-
trations; chest radiography, and dynamic CT and/or PET
of the abdomen and pelvis. All tumors were staged using
the American Joint Committee on Cancer (AJCC), 6th
edition, and were classified as stage cT4 (unresectable
disease), based on the CT scans, with tumor extension
to the celiac axis or superior mesenteric artery or occlu-
sion of the superior mesenteric-portal venous conflu-
ence. Primary tumors were measured bi-dimensionally,
with lymph node involvement defined by the presence of
a lymph node ≥1 cm in the short-axis, with a spiculated
or indistinct border, or with a mottled heterogeneous
pattern on CT with or without PET (n = 87) [11]. Table 1
shows the baseline patient characteristics.
Treatment
Radiotherapy
Prior to RT, all patients underwent CT simulation, with
their targets defined in accordance with the Inter-
national Commission on Radiation Units and Measure-
ments Report 50. The gross tumor volume (GTV)
encompassed the gross tumor, as defined by contrast CT
or PET scan. The clinical target volume (CTV) included
the GTV and the volumes of regional lymph nodes, in-
cluding the porta hepatic, pericholedochal, celiac, and
pancreaticoduodenal nodes. The initial and boot plan-
ning target volume (PTV) included the CTV and GTV
plus a 5–10 mm margin. All patients underwent three-
dimensional treatment planning, such that the PTV
would be encompassed by a 90% isodose volume of the
prescribed dose.
An initial dose of 45 Gy in 25 fractions was delivered
to the primary tumor and regional lymph nodes,
followed by a boost of 10.8 Gy in 6 fractions to the gross
tumor, 5 days a week. All patients received a total radi-
ation dose of 55.8 Gy in 31 fractions.
Chemotherapy
Capecitabine or 5-FU was delivered concurrently with
RT. The capecitabine group received an oral dose of
800 mg/m2 twice daily for the duration of RT with week-
end breaks. The 5-FU group received two cycles of intra-
venous bolus injection of 5-FU (400 mg/m2/d) for 3 days
in the first and fifth weeks of RT.
Treatment after CRT and evaluation
Following completion of CRT, patients were evaluated clin-
ically and underwent CT scans of the abdomen, chest radi-
ography, and serum CA 19–9 measurements to determine
tumor response and resectability. Patients who had resect-
able disease after CRT was considered for surgical resection,
whereas patients who still had unresectable disease were
Table 1 Patient characteristics
Characteristic Capecitabine (n = 52), n (%) 5-FU (n = 46), n (%) p-value
Gender Male 32 (61.5) 31(67.4) 0.173†
Female 20 (38.5) 15 (32.6)
Age (years) Median (range) 63 (36–77) 66 (41–80) 0.126‡
Mean ± SE 62.1 ± 1.3 65.0 ± 1.4
<65 31 (59.6) 19 (41.3) 0.105†
≥65 21 (40.4) 27 (58.7)
Tumor location Head 30 (57.7) 30 (65.2) 0.445†
Body/tail 22 (42.3) 16 (34.8)
Tumor size* (cm) Median (range) 3.8 (2.4–7.4) 3.9 (2.5–10) 0.297‡
Mean ± SE 4.0 ± 0.1 4.3 ± 0.2
<4 28 (53.8) 23 (50) 0.840‡
≥4 24 (46.2) 23 (50)
Histological differentiation Well/moderate 13 (25) 12 (26.1) 0.617†
Poor 2 (3.9) 4 (8.7)
Not specified 37 (71.1) 20 (65.2)
cN classification N0 32 (61.5) 25 (54.3) 0.471†
N1 20 (38.5) 21 (45.7)
CEA (ng/ mL) Median (range) 4.2 (1.2–31.9) 3.8 (1.0–56.1) 0.493‡
Mean ± SE 6.4 ± 0.9 7.7 ± 1.7
<5 31 (59.6) 29 (63.0) 0.836†
≥5 21 (40.6) 17 (37.0)
Pretreatment CA 19–9 level (U/mL) Median (range) 218.5 (5.0–11445) 191.5 (5.0–4150) 0.056‡
Mean ± SE 1179.6 ± 307.3 531.1 ± 130.6
<400 29 (55.8) 31 (67.4) 0.300†
≥400 23 (44.2) 15 (32.6)
Abbreviations: FU fluorouracil, SE standard error, CEA carcinoembryonic antigen, CA 19–9 carbohydrate antigen 19–9, CRT chemoradiotherapy.
*Maximum diameter of the primary tumor.
†Fisher’s exact test, two-tailed.
‡t-test, two-tailed.
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m2over 30 minutes intravenously once weekly for 3 of every
4 weeks). Patients who refused further chemotherapy or had
poor performance status received supportive care.
Serum samples for measurement of CA 19–9 were
obtained from all patients within 2 weeks of the initi-
ation of CRT (pre-treatment level) and 1 month after
CRT (post-treatment level). The percent decrease in CA
19–9 concentration was calculated as: CA 19–9 percent
decrease (%) = [(pre-treatment CA 19–9 – post-
treatment CA 19–9)/pre-treatment CA 19–9] × 100.
Tumor responses were determined by comparison of CT
scans taken before and 1 month after CRT using the Re-
sponse Evaluation Criteria in Solid Tumors guidelines
[12]. A complete response (CR) was defined as the dis-
appearance of the primary tumor. A partial response
(PR) was defined as ≥30% reduction in the longest diam-
eter of the primary tumor. Progressive disease (PD) was
defined as a ≥20% increase in the longest diameter ofthe primary tumor or the appearance of one or more
new lesions. Stable disease (SD) was defined as a re-
sponse that did not qualify as a PR or a PD. Objective
response rates were calculated as the rate of CR + PR.
Patients with CR or PR were considered “Responders”,
and those with SD or PD were considered “Non-re-
sponders”. Toxicity was recorded according to the Na-
tional Cancer Institute Common Terminology Criteria
for Adverse Events, version 3.0. Due to difficulties in ac-
curately scoring lower grades of acute toxicity in patients
with pancreatic cancer, only grade 3 or higher acute tox-
icities are compared.
Follow-up and statistical analysis
After completion of treatment, patients were given
follow-up examinations every 2–4 weeks for the first
3 months, and then every 3 months. For most patients,
follow-up evaluations at each visit included a physical
examination, complete blood count, liver function test,
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dynamic CT scan of the abdomen and pelvis. Recurrence
was proven by biopsy or cytology, and/or by radiological
findings that indicated an increase in tumor size.
A pretreatment serum CA 19–9 of 400 U/mL, the sig-
nificant cutoff point in our previous reports [13,14], or
a 40% decrease in CA 19–9, close to the median value
for each group, was chosen as a cutoff point for com-
parison of patient survival rates. Parameters in the
capecitabine and 5-FU groups were compared using chi-
square tests, Fisher’s exact tests, and t-tests, as applic-
able. Overall survival (OS) was defined as the interval
from the commencement of CRT to the date of death or
last follow-up and its probability was calculated by the
Kaplan–Meier method. Univariate and multivariate ana-
lyses were performed using the log rank test and Cox’s
proportional hazard model, respectively, to evaluate
prognostic factors associated with OS. All statistical tests
were two-sided and were performed using STATA soft-
ware (ver. 9.0; Stata Corp., College Station, TX). P values
less than 0.05 were considered statistically significant.Results
Patient characteristics
The clinical parameters of the capecitabine and 5-FU
groups were similar (Table 2). The median follow-up
time for all patients was 12.3 months (range, 2.3–
65.8 months) and was similar in the capecitabine and 5-
FU groups [12.6 months (range, 2.3–39.2 months) vs.
11.2 months (range, 4.6–65.8 months), p =0.837].Table 2 Comparison of toxicities* between the capecitabine a
Capecitabine (n = 52), n
Type of toxic effect Grade 1 Grade 2 Grade 3 Grad
Hematologic toxicity
Leukopenia 22 8 0 0
Anemia 36 1 0 0
Thrombocytopenia 18 3 0 0
Nonhematologic toxicity
Hand-foot syndrome 3 0 0 0
Anorexia 19 0 0 0
Vomiting 6 6 0 0
Diarrhea 5 2 0 0
Constipation 1 0 0 0
Abdominal pain 14 1 0 0
Stomatitis 21 0 0 0
Abbreviations: same as Table 1.
Some patients experienced more than one toxicity.
*National Cancer Institute Common Terminology Criteria for Adverse Events, version
† Fisher’s exact test, two-tailed.Toxicity
Treatment was well tolerated in both groups and there
were no treatment-related deaths. The details of the dis-
tribution of toxicities between the capecitabine and 5-
FU groups are summarized in Table 2. None of the pa-
tients in the capecitabine group developed Grade ≥3
toxicities, whereas 4 patients each (8.7%) in the 5-FU
group developed Grade ≥3 hematologic and non-
hematologic toxicities (p = 0.045 each).Tumor response and overall survival
Overall and primary tumor responses were evaluated
one month after CRT by imaging modalities, except in
one patient who had no available radiologic images after
CRT. No patient in either group achieved a CR in pri-
mary tumor or overall response. Primary tumor response
was as follows: PR in 29 patients (29.9%), SD in 67
(69.1%), and PD in 1(1.0%). Overall tumor response was
as follows: PR in 14 patients (14.4%), SD in 25 (25.8%),
and PD in 58 (59.8%). Of the 58 patients with overall
tumor responses of PD, 57 (83.6%) had distant metasta-
ses, regardless of primary tumor response (i.e., 15 had
primary tumor responses of PR and 42 of SD); one pa-
tient (1%) showed primary tumor progression without
distant metastasis. Overall and primary tumor responses
and percent decreases in CA 19–9 concentrations in the
capecitabine and 5-FU groups are summarized in Table 3.
None of these between group differences was statistically
significant (p > 0.05 each). Of the 98 patients, 7 (7.1%)
underwent surgical resection, with 5 being marginnd 5-fluorouracil (5-FU) groups
5-FU (n = 46), n
e 4 Grade 1 Grade 2 Grade 3 Grade 4 p-value†
6 9 1 1 0.007
23 7 2 0 0.022
15 1 0 0 0.719
1 0 0 0 0.620
18 2 1 0 0.283
14 8 2 0 0.010
6 2 1 0 0.860
3 0 0 0 0.339
12 1 0 0 1.000
30 0 0 0 0.016
3.0.
Table 3 Tumor responses* in the capecitabine and 5-fluorouracil (5-FU) groups
Response Capecitabine (n = 51†), n (%) 5-FU (n = 46), n (%) p-value
Primary tumor 0.658‡
Complete response 0 (0) 0 (0)
Partial response 16 (30.7) 13(28.2)
Stable disease 35 (67.3) 32 (69.6)
Progressive disease 0 (0) 1 (2.2)
Overall 0.273‡
Complete response 0 (0) 0 (0)
Partial response 7 (13.7) 7 (15.2)
Stable disease 10 (19.6) 15 (32.6)
Progressive disease 34 (66.7) 24 (52.2)
CA 19–9 percent decrease (%)
Median (range) 38.9 (−624.1–98.9) 39.7 (−383.4–98.6) 0.484§
Mean ± SE −1.9 ± 19.5 16.2 ± 15.8
<40 29 (55.8) 26 (56.5) 1.000‡
≥40 23 (44.2) 20 (43.5)
*Response assessment in solid tumors (RECIST) version 1.1.
†No available radiologic image for one patient.
‡Fisher’s exact test, two-tailed.
§t-test, two-tailed.
Figure 1 Overall survival curves of the capecitabine and 5-FU
groups. *log-rank test.
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resectability were similar in the capecitabine and 5-FU
groups [4/52 (7.7%) vs. 3/46 (6.5%), p = 1.000]. Of the 7
resected patients, 2 developed locoregional recurrence,
3.5 and 5.5 months later, with the remaining 5 continu-
ing to be locoregionally controlled. After completion of
CRT, 47 patients (48%), received gemcitabine based
chemotherapy until disease progression, treatment-
limiting toxicity, or death; the median number of
chemotherapy cycles was 3 (range, 1–17). The remaining
51 patients (52%) did not receive maintenance chemo-
therapy because of patient refusal or poor performance
status. The distribution of patients receiving mainten-
ance chemotherapy were similar in the capecitabine and
5-FU groups [26/52 (50%) vs. 21/46 (45.7%), p = 0.667].
At the time of analysis, 96 patients (92.9%) had died
and 2 (7.1%) remained alive. The median OS time for all
patients was 12.1 months [95% confidence interval (CI),
9.8–13.4 months] and the median OS times for the
capecitabine and 5-FU groups were 12.5 months (95%
CI, 10.7–13.7 months)and 11.6 months (95% CI, 8.5–
13.8 months), respectively (p = 0.655) (Figure 1). Table 4
summarizes the results of univariate analysis for the
prognostic factors associated with OS. Maintenance
chemotherapy (No vs. Yes) was significantly associated
with OS (10.6 months vs. 14.4 months, p < 0.001) and N
classification (N0 vs. N1; 13.0 months vs. 10.7 months,
p = 0.069) and pretreatment CA 19–9 level (< 400vs. ≥
400 U/mL; 12.7 months vs. 9.7 months, p = 0.063)
showed marginal associations with OS, whereas none ofthe other parameters was significantly associated with
OS (p > 0.05) (Table 4). Multivariate analysis showed that
pretreatment CA 19–9 level and maintenance chemo-
therapy were independent prognostic factors for OS
(p < 0.05) (Table 5).
Table 4 Univariate analysis of factors influencing overall survival
Overall survival
Median (95% CI), months p-value*
Gender Male 11.6 (9.2–14.0) 0.426
Female 13.4 (12.2–14.6)
Age (years) <65 12.0 (10.9–13.1) 0.608
≥65 12.1 (9.8–14.4)
Tumor location Head 11.6 (9.0–13.0) 0.413
Body/tail 13.0 (9.5–15.6)
Tumor size(cm) <4 12.7 (9.6–13.8) 0.664
≥4 12.0 (9.3–13.4)
Histological differentiation Well/moderate 13.4 (10.6–15.6) 0.717
Poor 8.8 (5.9–25.7)
Not specified 12.2 (9.5–13.2)
cN classification N0 13.0 (10.6–15.0) 0.069
N1 10.7 (8.8–12.7)
CEA (ng/ mL) <5 12.6 (9.8–13.4) 0.190
≥5 11.8 (8.3–13.7)
Pretreatment CA 19–9 level (U/mL) <400 12.7 (11.6–15.0) 0.063
≥400 9.7 (8.3–12.7)
Concurrent chemotherapy Capecitabine 12.5 (10.7–13.7) 0.655
5-FU 11.6 (8.5–13.8)
Primary tumor response Responder 13.6 (8.6–18.9) 0.165
Nonresponder 11.9 (9.6–13.0)
CA 19–9 percent decrease (%) <40 11.6 (9.0–13.1) 0.639
≥40 12.7 (10.7–14.4)
Post-CRT surgery No 12.2 (9.8–13.4) 0.883
Yes 12.0 (5.9–25.7)
Maintenance chemotherapy No 10.6 (8.5–12.1) <0.001
Yes 14.4 (11.7–18.8)
Abbreviations: Responder complete or partial response, Nonresponder stable disease or progressive disease NS not significant, p > 0.05, others are same as in
Table 1.
*Log rank test.
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We found that the rates of Grade ≥3 hematologic (0%
vs. 8.7%, p = 0.045) and non-hematologic (0% vs. 8.7%,
p = 0.045) toxicities were significantly lower in the
capecitabine group than in the 5-FU group. Lower tox-
icity rates may have been due to the pharmacodynamic
advantages of oral capecitabine relative to bolus 5-FU
[15]. Capecitabine is a tumor-selective fluoropyrimidineTable 5 Multivariate analysis of factors influencing overall su
Factor H




Abbreviations: CI confidence interval, other abbreviations are as in Table 1.
*Multivariate analysis using the Cox proportional hazards model.carbamate that is converted to active 5-FU by TP, an en-
zyme of higher abundance in tumor than in normal tis-
sue that is upregulated by radiation in tumor but not in
normal tissue [9,10]. Thus, theoretically, capecitabine
could show lower rates of toxicity than bolus 5-FU. A
previous study found that the rate of Grade ≥3
hematologic toxicity was lower in patients receiving
capecitabine than 5-FU during preoperative CRT forrvival
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similar to our results, but that rates of Grade ≥3 diarrhea
(8.6% vs. 2.1%, p = 0.006) and hand-foot syndrome (2%
vs. 0%, p = 0.061) were higher in the capecitabine group
[16]. However, a phase II trial of induction chemother-
apy with gemcitabine and cisplatin followed by CRT
with capecitabine in patients with locally advanced pan-
creatic cancer showed that the rates of Grade ≥3 diar-
rhea (5.4%) and hand-foot syndrome (0%) were low
during CRT [17], similar to our findings. These findings
implied that the lower rates of Grade ≥3 non-
hematologic toxicity in the capecitabine than in the 5-
FU group in our study maybe due to genetic differences
in tolerability or susceptibility to capecitabine between
Caucasians and Asians, as the conversion rate of tegafur
to fluorouracil is different between Caucasians and
Asians due to polymorphic differences in the CYP2A6
gene [18,19]. However, due to the relatively small number
of patients in the capecitabine group (n = 52), which may
be insufficient to determine the overall actual toxicity
rates thoroughly and low incidence of toxicities in western
study treated with CRT with capecitabine [20], more
comprehensive and larger-scale studies should be needed.
Protracted infusion of 5-FU and capecitabine, which
prolongs the exposure of non-cycling tumor cells to 5-
FU, may enhance cytotoxicity relative to bolus 5-FU.
Protracted infusion of 5-FU or capecitabine during adju-
vant CRT has been shown to improve relapse-free sur-
vival (RFS) and OS, compared with bolus 5-FU, in
patients with rectal cancer [16,21]. In contrast, the
Intergroup 0144 study, which compared different 5-FU
based chemotherapeutic regimens in rectal cancer, found
that protracted and bolus infusion of 5-FU yielded simi-
lar RFS and OS, and our previous report [22] showed
that capecitabine and bolus 5-FU resulted in similar
radiologic and pathologic tumor responses in patients
receiving preoperative CRT for rectal cancer. However,
to date, it has been remained unclear whether chemo-
therapeutic regimens, among a protracted infusion of 5-
FU, capecitabine, or bolus injection of 5-FU, can result
in superior outcomes in patients with pancreatic cancer.
We found that capecitabine, which mimics the
protracted infusion of 5-FU, and bolus 5-FU yielded
similar tumor responses and overall survival in patients
with locally advanced pancreatic cancer.
A randomized trial found that, compared to5-FU,
gemcitabine yielded better outcomes, including allevi-
ation of disease-related symptoms and longer OS, in
patients with advanced, symptomatic pancreatic cancer
[23], and thus various dosages and schedules of
gemcitabine based chemotherapy, with or without RT,
have been tried to improve survival in locally advanced
pancreatic cancer patients [4-6,8]. These studies, how-
ever, showed that gemcitabine based chemotherapy,with or without oxaliplatin, paclitaxel, docetaxel, and
tyrosine kinase inhibitors, resulted in high rates of se-
vere toxicities, without survival benefits, compared
to 5-FU. Thus, 5-FU continues to be used as a concurrent
chemotherapeutic agent during CRT [5]. To evaluate the
effectiveness and safety of capecitabine, we compared out-
comes, including toxicity, tumor response and overall
survival, of RT plus capecitabine or bolus 5-FU, in
patients with locally advanced pancreatic cancer.
This study was retrospective and thus had certain in-
herent limitations. First, it included relatively small num-
bers of patients in the capecitabine (n = 52) and 5-FU
(n = 46) groups, which may have been insufficient to
compare outcomes thoroughly. Second, this was a retro-
spective comparison study of two groups with different
chemotherapeutic regimens, not a randomized trial.
Thus, further larger scaled and comprehensive studies
are required to accurately compare the outcomes of
these two chemotherapy regimens in patients with lo-
cally advanced pancreatic cancer. However, in present
study, the characteristics of patients in the two groups
did not differ significantly, and each chemotherapeutic
regimen was decided according to patient’s preferences.
Conclusion
In conclusion, we compared the outcomes of CRT with
capecitabine or bolus 5-FU in patients with locally ad-
vanced pancreatic cancer. We found that CRT with
capecitabine had low toxicity rates, but yielded similar
tumor responses and overall survival compared with
CRT with bolus 5-FU. These findings suggest that
capecitabine may be a safe and feasible chemotherapy
regimen in patients with locally advanced pancreatic
cancer treated with CRT.
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